HEMATOLOGY
Meeting highlight View All

Pinnacle 4-year data from OPTIC supports durable efficacy of ponatinib in CP-CML with BCR::ABL1 T315I mutation

29 Dec 2024
thumb

Professor Michael Deininger

Adjunct Professor of Hematology and Hematologic Malignancies,
Department of Internal Medicine, University of Utah, United States

Research Spotlight View All

Unlocking the full potential of CAR T-cell therapy in R/R MM: A consensus from the IMWG Immunotherapy Committee

Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has emerged as a transformative treatment for relapsed or refractory multiple myeloma (R/R MM), which remains challenging despite advances in conventional therapies.1 Targeting B-cell maturation antigen (BCMA), consistently expressed on malignant

22 May 2025

Lancet Oncol. 2024

Lin Y, Qiu L, Usmani S, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O’Dwyer M, Schjesvold F, Sidana S, van de Donk NWCJ, Weisel K, Zweegman S, Raje N, Rodriguez Otero P, Anderson Jr LD, Kumar S, Martin T, International Myeloma Working Group. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374-e387.

thumb

Dr. Sivakumar Palaniappan

Consultant Hematologist,
Pantai Hospital Kuala Lumpur,
Kuala Lumpur, Malaysia

case review View All
news & perspective View All
infographics View All

The Hidden Blueprint: CGAT Reveals Key Insights for Myelofibrosis Transplant

06 Apr 2025